Retatrutide — designated GLP3-R — is the world’s first triple GLP-1/GIP/Glucagon receptor agonist. Where Semaglutide targets one
receptor and Tirzepatide targets two, Retatrutide simultaneously activates all three incretin and metabolic hormone pathways. The
addition of glucagon receptor agonism drives enhanced energy expenditure and significant hepatic fat reduction not observed with
single or dual agonists. Published Phase 2 data (Nature Medicine 2024) demonstrated 24.2% body weight reduction at 48 weeks and
significant HbA1c improvement in T2D research models. The most advanced incretin research compound currently available.